mRNA expression of GPPP genes in response to HDACi. (A) GPPP mRNA levels in response to NaBu as assessed by qRT-PCR. (A) WT (ie, non-G6PD–deficient) B-cell line was treated with 3 mM NaBu. Data are normalized to t = 0 levels (n = 3). HK1, GPI, PFKL, ALDOA, TPI, GAPDH, PGK1, PGAM, ENO1, PK, and BPGM are part of the glycolytic pathway, and G6PD, PGLS, PGD, RPE, TKT, and TALDO1 are part of the pentose phosphate pathway. (B) GPPP mRNA expression extracted from the GSE15735 data set. CD4⁺ T cells were treated with 100 ng/mL trichostatin (TSA) and 2 mM NaBu for 12 hours (n = 3). (C) mRNA levels of GPPP genes as assessed by GEP analysis of day 5 CB CD34⁺-derived proerythroblasts after 6-hour treatment with 1 mM NaBu (n = 3). (D) mRNA levels of GPPP genes in CB CD34⁺-generated erythroblasts after NaBu treatment for 48 hours. *P < .05; **P < .01; ***P < .001.